Tom is Senior Investment Director at Debiopharm Innovation Fund, the strategic fund of Debiopharm, a drug developer in oncology based in Lausanne. We are investing in startups developing digital tools to transform drug development, which includes in-silico approaches, AI-driven biomarker discovery and clinical trials tech.We invest at seed and Series A in Europe, North America, and Israel. Tom is a molecular microbiologist by training and has worked in the commercialization of life science technologies in start-ups and established companies in Europe and the USA (including Molecular Devices Corp, Covalys, Med Discovery, Debiopharm) for longer than he cares to admit. He is excited to bring his broad experience to the digital health revolution, helping start-ups build value and make a meaningful impact.. He is currently a Director on the boards of Nucleai, Altis Labs, BC Platforms, and Immunexpress. Hands-on experience includes operations, late-stage product development & marketing, business development, and investment.